Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (331-340 of 379) with videos related to

Pageof 38
Sort By:
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
British Journal of Haematology|November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
The Lancet. Oncology|February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2003
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapyHendrik Pels, Ingo G H Schmidt-Wolf, Axel Glasmacher, et al.
Annals of Neurology|March 13, 2010
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphomaAnnika Juergens, Hendrik Pels, Sabine Rogowski, et al.
Journal of Neuro-Oncology|October 22, 2008
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II studyHendrik Pels, Annika Juergens, Axel Glasmacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trialAndreas Engert, Jeremy Franklin, Hans Theodor Eich, et al.
Oncotarget|April 23, 2016
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitroHinrich P Hansen, Ahmad Trad, Maria Dams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2003
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study GroupAndreas Engert, Petra Schiller, Andreas Josting, et al.
Haematologica|May 9, 2020
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPPRon Daniel Jachimowicz, Luise Pieper, Sarah Reinke, et al.
Pageof 38

Showing results (331-340 of 379) with videos related to

Sort By:
Pageof 38
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
British Journal of Haematology|November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
The Lancet. Oncology|February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2003
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapyHendrik Pels, Ingo G H Schmidt-Wolf, Axel Glasmacher, et al.
Annals of Neurology|March 13, 2010
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphomaAnnika Juergens, Hendrik Pels, Sabine Rogowski, et al.
Journal of Neuro-Oncology|October 22, 2008
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II studyHendrik Pels, Annika Juergens, Axel Glasmacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trialAndreas Engert, Jeremy Franklin, Hans Theodor Eich, et al.
Oncotarget|April 23, 2016
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitroHinrich P Hansen, Ahmad Trad, Maria Dams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2003
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study GroupAndreas Engert, Petra Schiller, Andreas Josting, et al.
Haematologica|May 9, 2020
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPPRon Daniel Jachimowicz, Luise Pieper, Sarah Reinke, et al.
Pageof 38